GlassScriptPhysician profile
Harold C Barlekamp
NPI 1639179963
$3,182.77
in general payments reported to CMS, 2019-2025
32 companies · $751 in 2025
The $751 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $435 · 2021: $33.63 · 2022: $93.85 · 2023: $373 · 2024: $695 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $712.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $312.83 | 2022-2025 | |
| Pfizer INC. | $263.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $257.78 | 2019-2023 | |
| Exact Sciences Corporation | $158.02 | 2023-2025 | Cologuard Collection Kit |
| Avadel Cns Pharmaceuticals, LLC | $125.00 | 2025 | Lumryz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.74 | 2023-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $102.36 | 2023-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $95.45 | 2024-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $92.20 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $85.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Radius Health, INC. | $84.05 | 2023-2025 | Tymlos |
| Dexcom, INC. | $78.21 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.88 | 2019-2025 | Ofev, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $61.94 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.09 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $58.49 | 2019-2025 | Capvaxive |
| Abbott Laboratories | $57.71 | 2021-2023 | Freestyle Libre 2 |
| Inspire Medical Systems, INC. | $53.06 | 2024 | Inspire |
| Lundbeck LLC | $52.78 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $52.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.40 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $33.76 | 2025 | Rexulti |
| Allergan, INC. | $25.96 | 2019 | |
| Axsome Therapeutics, INC. | $21.79 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $20.71 | 2019 | |
| Astellas Pharma US INC | $20.17 | 2023 | Veozah |
| Scilex Pharmaceuticals INC. | $17.65 | 2019 | |
| Phadia US INC. | $15.63 | 2023 | Immunocap |
| Actelion Pharmaceuticals US, INC. | $13.21 | 2023 | Uptravi, Opsumit |
| Biohaven Pharmaceutical Holding Company LTD. | $12.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Barlekamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.